Bristol Myers Squibb Co is embroiled in a $6.4 billion lawsuit over allegations of delaying the launch of its Breyanzi cancer drug, raising scrutiny on the company's operational decisions. Despite these legal challenges, the firm recently completed an $80.3 billion acquisition of Celgene Corp and must now pay Celgene shareholders an additional $9 per share tied to FDA approval deadlines. The FDA approved Breyanzi on February 5, 2021, but concerns remain about the company's efforts to secure earlier authorization. As Bristol Myers gears up for its next earnings report, analysts anticipate a slight decline in EPS to $1.90, reflecting ongoing investor skepticism.
“Bristol Myers Squibb Co · is accused of delaying · Breyanzi cancer drug · $6.4 billion lawsuit”
“Bristol Myers Squibb Co · acquired · Celgene Corp · $80.3 billion”
“Bristol Myers Squibb Co · was required to pay · Celgene shareholders · $9 per share”
“Bristol Myers Squibb Co · is accused of delaying · Breyanzi cancer drug · $6.4 billion lawsuit”
“Bristol Myers · claimed it was never properly notified about · default on merger obligations · UMB Bank NA”
“Bristol Myers · failed to use · diligent efforts · to obtain approval for Breyanzi by Dec. 31, 2020”
“Bristol Myers · won FDA approval for · Breyanzi · on Feb. 5, 2021”
“Bristol Myers · agreed to pay Celgene shareholders · an extra $9 per share in cash · if it won U.S. approval by specified deadlines”
“Bristol Myers Squibb · announced · new post-hoc analyses · from the Zeposia Phase 3 DAYBREAK trial”
“Bristol Myers Squibb · is inspired by · a single vision · transforming patients’ lives through science”
“Bristol Myers Squibb · is a · global biopharmaceutical company”
“Bristol-Myers Squibb · has rallied · percentage · 19%”
.svg&width=160)